LY2409021 + gemfibrozil

This is a **combination drug consisting of LY2409021 and gemfibrozil**. - **LY2409021** is a glucagon receptor antagonist developed primarily for the treatment of type 2 diabetes mellitus. Its mechanism involves inhibiting the glucagon receptor, thereby reducing hepatic glucose output and lowering blood glucose levels. - **Gemfibrozil** is a fibric acid derivative (fibrate) used to lower triglyceride levels and increase high-density lipoprotein (HDL) in patients with hyperlipidemia. Its primary action is to activate peroxisome proliferator-activated receptor-α (PPARα), which alters lipid metabolism, leading to reduced circulating triglycerides and changes in cholesterol fractions[3][5]. This combination is not a standard co-formulation and appears to represent a combination regimen used in research or drug interaction studies, rather than a commercial product. There are no unique brand or trade names associated specifically with the combination.

Other names

LY2409021LY-2409021LY 2409021gemfibrozil